sameAs
Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosisModulating sensitivity to drug-induced apoptosis: the future for chemotherapy?Protein kinase C delta is phosphorylated on five novel Ser/Thr sites following inducible overexpression in human colorectal cancer cellsDamage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate.Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factorsHypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1AlphaTracking genomic cancer evolution for precision medicine: the lung TRACERx studyExpression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.Imaging biomarker roadmap for cancer studiesLiquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion.Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.A hierarchical statistical modeling approach to analyze proteomic isobaric tag for relative and absolute quantitation data.Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry.Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors.A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC.Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.Cell Sensitivity Assays : Detection of Apoptotic Cells In Vitro Using the TUNEL Assay.Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs.Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity.Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancerIncreases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.Circulating tumor cells as a window on metastasis biology in lung cancer.Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.Method validation of circulating tumour cell enumeration at low cell counts.Biological mechanisms linking obesity and cancer risk: new perspectives.A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells.Circulating tumour cells: their utility in cancer management and predicting outcomes.Mitochondrial membrane permeabilisation by Bax/Bak.
P50
Q24670370-263384BF-518A-4EFD-96BD-96F93FA5F650Q24801341-68E993F1-7371-4D4C-9578-199B97E817F6Q28255129-2ECE7FBB-531B-4359-B398-E3788910692DQ28364008-8C539DE0-E38C-4911-BED5-F85E671022E9Q28378389-E8D7B450-0784-4BE0-9315-125619FDC7F9Q28533909-4827C7AA-6911-4EC0-B04B-D6A9AC0D3512Q28655985-09CEAB3B-8D00-4CFC-A622-AF7451B6C627Q30163857-933A8F03-2B39-4A94-BCDD-1E89460CCFEAQ30242020-DBC62B6D-DA52-4C59-BB22-8E1BF6CDE72EQ30573699-C4028DBE-D4A0-48AD-A5E2-E7B07B5A5C2EQ30664020-F7687DF2-AE92-4B76-BBED-0B1396D455D6Q30717069-5337DCC1-03F9-4748-9D68-B13F44C44F6CQ33279321-A33AE7B0-F42B-4742-9268-404CC5E20539Q33292494-3E7DE122-FA93-46DA-AB51-269C64D38903Q33383417-E1E9E06F-28C5-4CEA-B651-77145276F183Q33393931-C9999302-FA7B-482F-B0FC-EE088B5C1888Q33400716-5FB1C8CB-C8CE-43FB-A67D-2691F3E5D8F2Q33503545-5230820B-BB8F-4E0B-B6E2-D939A9F668A5Q33529279-1BF7AD2C-E27C-4857-8E3F-AE46DDBDC9E5Q33620098-96FD1D80-C7FA-4B0B-9751-5CE74FBE7C87Q33658526-AC7400CB-343C-4F25-86A2-40DA64B36291Q33836977-863986A6-C62C-43D4-AD09-55F5740A6784Q33847836-3CA6385E-A111-4593-B906-2B865748121AQ33901504-2189A286-6FDB-49E6-A161-95BDF54DF7ADQ34012615-B5533D37-909E-4B30-A073-2F822AEFB5F6Q34059976-57136A7E-DCC3-410E-9468-72C96F658436Q34134697-72C616E0-4ED7-469B-8ABD-DDB08FEFFDC9Q34241985-BFB50498-6E31-4EFE-AD7A-9FA15D61CFCFQ34582207-7AB56FC4-9AE4-489D-88E3-517FF48DBDC0Q34585402-6ABFAD4B-6746-4F1B-B980-E48C10FB935EQ34627911-3F5933EB-2538-489C-AC36-E3EE8631CE17Q34634536-FC024A30-8E97-4883-8908-B1B5FD365E08Q34756160-7653B67F-4004-447C-8F7E-263D822192BBQ34763661-4F3D5A3C-85EC-41D9-BD17-E5664E7922FDQ34984977-D2F6F25B-B931-44EF-985C-076006703FBCQ35007716-E15C1BF9-6488-47FB-AE17-D89097795DF5Q35021208-08E37E1C-49EA-4D10-9151-750F1D846405Q35060289-1035512B-1F9B-4DAE-B4F3-FCB9E331E377Q35076325-2666C5FC-A741-460A-B6F3-AE7C97FEC006Q35120714-855F706E-58EC-49A3-85BB-746516B6D13F
P50
description
Professor of Cancer Pharmacology
@en
onderzoeker
@nl
name
Caroline Dive
@ast
Caroline Dive
@en
Caroline Dive
@es
Caroline Dive
@nl
Caroline Dive
@sl
type
label
Caroline Dive
@ast
Caroline Dive
@en
Caroline Dive
@es
Caroline Dive
@nl
Caroline Dive
@sl
prefLabel
Caroline Dive
@ast
Caroline Dive
@en
Caroline Dive
@es
Caroline Dive
@nl
Caroline Dive
@sl
P166
P214
P244
P101
P166
P21
P213
0000 0000 3432 1727
P214
P244
P31
P496
0000-0002-1726-8850
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-n99034532